Master Your Peptide Protocol

CJC-1295 (no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a tetrasubstituted form of hGRF(1-29) with four amino acid substitutions that provide enhanced stability against enzymatic degradation, particularly by dipeptidyl peptidase-IV (DPP-IV). Unlike CJC-1295 with DAC, this version lacks the drug affinity complex (DAC) that binds to albumin, resulting in a shorter half-life but more pulsatile growth hormone release that mimics natural physiological patterns. The peptide works by binding to GHRH receptors on the anterior pituitary gland to stimulate growth hormone secretion.

BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide consisting of 15 amino acids, isolated from human gastric juice. It has demonstrated remarkable stability against enzymatic degradation, hydrolysis, and even gastric juice. In extensive preclinical research, BPC-157 has shown pleiotropic beneficial effects including accelerated healing of tendons, muscles, ligaments, bones, and the gastrointestinal tract. It has been in clinical trials for inflammatory bowel disease (IBD) and multiple sclerosis. Unlike many peptides, BPC-157 can be administered orally as well as by injection due to its stability in the GI tract.

Testosterone Enanthate is an injectable testosterone ester widely used for testosterone replacement therapy (TRT) in hypogonadal men. It is one of the most commonly used testosterone formulations globally, particularly in Europe. The enanthate ester provides a half-life of approximately 4-5 days, allowing for weekly or biweekly injections. It has nearly identical pharmacokinetics to testosterone cypionate and is considered interchangeable for clinical purposes.

Pinealon (EDR, Glu-Asp-Arg) is a synthetic short tripeptide developed by Russian scientist Vladimir Khavinson and colleagues as part of the bioregulatory peptide research program. The peptide is designed to target the pineal gland and central nervous system. Research has shown that this ultrashort peptide can penetrate cell membranes and enter the nucleus, where it may interact with DNA and regulate gene expression epigenetically. Pinealon has demonstrated antioxidant, neuroprotective, and potential anti-aging properties in various preclinical studies.

Retatrutide (LY3437943) is a novel investigational triple-hormone receptor agonist developed by Eli Lilly that activates the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It represents the next generation of incretin-based therapies beyond dual agonists like tirzepatide (GIP/GLP-1). By combining three complementary mechanisms—GLP-1 for appetite suppression and glucose control, GIP for enhanced metabolic effects and insulin sensitivity, and glucagon for increased energy expenditure and fat oxidation—retatrutide produces profound weight loss that exceeds current approved obesity medications. In Phase 2 clinical trials (2023), retatrutide achieved up to 24% body weight reduction in obese adults over 48 weeks, making it one of the most effective weight-loss medications ever tested. It is currently in Phase 3 development for obesity and type 2 diabetes. Retatrutide is administered once weekly via subcutaneous injection and is designed for long-term chronic use.

Tirzepatide is an FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes (Mounjaro, approved 2022) and obesity (Zepbound, approved 2023). It is the first FDA-approved dual incretin receptor agonist, representing a major advancement beyond single GLP-1 agonists like semaglutide. By activating both GIP and GLP-1 receptors, tirzepatide produces superior weight loss and glycemic control compared to GLP-1 monotherapy. In clinical trials, tirzepatide achieved up to 22.5% body weight reduction in obese adults and HbA1c reductions of 2-2.5% in type 2 diabetes patients. Administered once weekly via subcutaneous injection, tirzepatide has become one of the most effective pharmacologic treatments for obesity ever approved. The dual agonism exploits complementary mechanisms: GLP-1 primarily drives appetite suppression and glucose control, while GIP enhances insulin sensitivity, modulates adipose tissue metabolism, and may amplify GLP-1's effects on satiety.

Tesamorelin (Egrifta) is a synthetic analog of human growth hormone-releasing hormone (GHRH, also known as growth hormone-releasing factor) that stimulates the synthesis and pulsatile release of endogenous growth hormone from the pituitary gland. It was approved by the FDA in November 2010 and is the first and only treatment specifically indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike direct growth hormone administration, tesamorelin stimulates natural, pulsatile GH release, which more closely mimics physiological patterns.

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Discovered in 1973, GHK (glycyl-L-histidyl-L-lysine) readily forms a complex with copper (Cu2+), enhancing its bioavailability. Plasma levels decline with age: approximately 200 ng/mL at age 20, decreasing to 80 ng/mL by age 60. The GHK sequence is present in the alpha 2(I) chain of type I collagen and the SPARC protein, and is released from tissues after injury to initiate tissue repair. GHK-Cu has been extensively studied for over four decades and is widely used in cosmetic and anti-aging products.

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. It is the most abundant member of the beta-thymosin family and plays a critical role in tissue repair, cell migration, blood vessel formation, and wound healing. TB-500 promotes angiogenesis, cell differentiation, and anti-inflammatory responses. It has been extensively studied for its regenerative properties in cardiac tissue, skin, corneal, and musculoskeletal healing applications.

Ipamorelin is a highly selective growth hormone-releasing peptide (GHRP) that stimulates the release of growth hormone from the pituitary gland. It is the first GHRP-receptor agonist with selectivity for GH release similar to that displayed by GHRH, distinguishing it from other GHRPs by not affecting ACTH, cortisol, prolactin, FSH, LH, or TSH levels even at doses over 200-fold higher than the ED50 for GH release.